Who are IV lignocaine bolus and infusion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lidocaine/Magnesium, Lidocaine + Prilocaine, Lidocaine aerosol 2.4% topical, bucain + fentanyl, Anesthesia (Lidocaine 15%), Buffered Lidocaine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iv-lignocaine-bolus-and-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

IV lignocaine bolus and infusion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IV lignocaine bolus and infusion (IV lignocaine bolus and infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic; Class IB antiarrhythmic agent. Area: Cardiovascular; Anesthesia.

marketed Local anesthetic; Class IB antiarrhythmic agent Voltage-gated sodium channels Cardiovascular; Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

IV lignocaine bolus and infusion (IV lignocaine bolus and infusion) — University of Auckland, New Zealand. Lignocaine (lidocaine) is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IV lignocaine bolus and infusion TARGET	IV lignocaine bolus and infusion	University of Auckland, New Zealand	marketed	Local anesthetic; Class IB antiarrhythmic agent	Voltage-gated sodium channels
Lidocaine/Magnesium	Lidocaine/Magnesium	University of Wisconsin, Madison	marketed	Local anesthetic combination	Voltage-gated sodium channels; NMDA receptor
Lidocaine + Prilocaine	Lidocaine + Prilocaine	Galeno Desenvolvimento de Pesquisas Clínicas	marketed	Local anesthetic	Voltage-gated sodium channels
Lidocaine aerosol 2.4% topical	Lidocaine aerosol 2.4% topical	Jiangang Song	marketed	Local anesthetic	Voltage-gated sodium channels
bucain + fentanyl	bucain + fentanyl	University of Debrecen	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (bucain); mu-opioid receptor (fentanyl)
Anesthesia (Lidocaine 15%)	Anesthesia (Lidocaine 15%)	Lumbini Medical College	marketed	Local anesthetic	Voltage-gated sodium channels
Buffered Lidocaine	Buffered Lidocaine	University of California, San Diego	marketed	Local anesthetic	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic; Class IB antiarrhythmic agent class)

University of Auckland, New Zealand · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IV lignocaine bolus and infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/iv-lignocaine-bolus-and-infusion. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab